[Edaily Reporter Kwon Oh Seok ] #ROKIT HEALTHCARE Inc. surged to the daily price limit early in the trading session. It appears that buying interest is surging following news that its wholly-owned U.S. subsidiary has entered the final stage of its listing on the Nasdaq Global Market.

According to MP Doctor on the 24th, as of 9:17 a.m., ROKIT HEALTHCARE Inc. is trading at 48,000 won, up 29.91% from the previous trading day.
Earlier today, the company issued a press release stating, “ROKIT America, Inc. (Nasdaq ticker: RKAM), a wholly-owned U.S. subsidiary established in 2019, has successfully completed the procedures related to Form S-1 with the U.S. Securities and Exchange Commission (SEC) and has entered the final stage of its listing on the Nasdaq Global Market.”
The completion of the SEC Form S-1 process signifies that the company has cleared the most critical hurdle toward entering the U.S. capital market. ROKIT America is currently awaiting the final outcome of its Nasdaq listing. Additionally, the company is successfully conducting a bookbuilding process with overseas institutional investors and plans to swiftly proceed with the remaining schedule, including the allocation of shares, determination of the offering price, and the commencement of trading.
Based on the initial public offering price indicated in the registration statement currently filed with the SEC, Rokit America’s projected market capitalization at the time of listing is approximately 4000억 won. Once the listing is complete, Rokit America will become the first subsidiary of a KOSDAQ-listed South Korean biotech company to be listed on the Nasdaq Global Market. With the 380억 won in investment expected to be secured locally, the company will pioneer long-term regenerative clinical trials and market development in North and South America.